Evonik Industries is a global leader in specialty chemicals, combining innovation and technological expertise to deliver solutions across a wide range of industries. Headquartered in Essen, Germany, the company operates in more than 100 countries and supports pharmaceutical and biopharmaceutical companies through its Evonik Health Care business, providing solutions from early development to commercial manufacturing.

Evonik’s leadership in silica technology dates back to 1942, when its predecessor Degussa pioneered the flame hydrolysis process for fumed silica production. With over 80 years of expertise in particle design and synthetic amorphous silica (SAS), Evonik remains at the forefront of silica innovation. Its proprietary production of chlorosilane, a key silica precursor, ensures reliable supply through a fully integrated value chain.

In the biopharma sector, Evonik offers a portfolio of high-quality cell culture media ingredients, including peptides, antioxidants, and synthetic cholesterol, designed to enhance manufacturing efficiency and cell culture performance. Supported by formulation expertise, regulatory guidance, and GMP-compliant manufacturing, Evonik is a trusted partner for biologics, vaccines, and advanced therapies, including cell and gene therapies.

For more information, please visit website